Zhonghua Yi Xue Za Zhi

Expert consensus on the clinical application of nutrient-stimulated hormone receptor agonist in the treatment of type 2 diabetes mellitus (2026 edition)

By Endocrinology and Metabolism Professional Committee, National Association of Health Industry and Enterprise Management

CommentaryIndustry & policy

The paper

Endocrinology and Metabolism Professional Committee, National Association of Health Industry and Enterprise Management

Zhonghua Yi Xue Za Zhi, 19 Aug 2026

doi.org/10.3760/cma.j.cn112137-20260527-01398 PubMed 42618499

Lancet4 Oct 2026
Retatrutide reduces bodyweight in obesity and type 2 diabetes
The New England Journal of Medicine4 Oct 2026
Survodutide reduces weight in adults with diabetes and obesity
Cell Metabolism8 Oct 2026
A triple-target drug cut body weight by up to 19.7% in a trial
The New England Journal of Medicine4 Oct 2026
Retatrutide reduces weight and pain in adults with obesity